

REMARKS/ARGUMENT


In response to the Office Action mailed April 5, 2001, Applicants select Group II drawn to a method of treating autoimmune diseases with traverse.

It is respectfully pointed out that this case is a continuation of application Serial Number 08/983,223 which was the national filing of a PCT application. Accordingly, it is respectfully submitted that unity of invention standards are applicable rather than restriction standards. Unity of invention standards call for a common special technical feature which is met in the instant case by the combination of the TNF receptor and DHEA. All of the reasons set forth in the Office Action are applicable to U.S. restriction practice rather than Unity of Invention practice and therefore are respectfully submitted to not be relevant.

Withdrawal of the requirement and the examination of all claims is respectfully solicited.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231, on May 4, 2001:

Edward A. Meilman

Name of applicant, assignee or
Registered Representative


Signature

May 4, 2001

Date of Signature

Respectfully submitted,



Edward A. Meilman
Registration No.: 24,735
OSTROLENK, FABER, GERB & SOFFEN, LLP
1180 Avenue of the Americas
New York, New York 10036-8403
Telephone: (212) 382-0700

EAM:mgs